Table 2. Association of Top Metabolites With the Progression of Gastric Lesions During Follow-up of the Validation Set Participantsa.
| Metabolite | Progression vs nonprogression for all participants with prospective follow-up | Progression vs nonprogression for IM cases only | ||||
|---|---|---|---|---|---|---|
| No./total No. | OR (95% CI) | P value | No./total No. | OR (95% CI) | P value | |
| sn-2 LysoPC(20:3) | 53/99 | 1.13 (0.80-1.59) | .27 | 9/31 | 0.72 (0.35-1.48) | .23 |
| sn-1 LysoPC(18:3) | 53/99 | 0.82 (0.59-1.15) | .17 | 9/31 | 0.58 (0.27-1.25) | .12 |
| α-Linolenic acid | 53/99 | 0.64 (0.45-0.91) | .02 | 9/31 | 0.42 (0.18-0.98) | .05 |
| Linoleic acid | 53/99 | 0.69 (0.48-0.99) | .05 | 9/31 | 0.43 (0.19-1.00) | .05 |
| Palmitic acid | 53/99 | 0.63 (0.43-0.92) | .02 | 9/31 | 0.32 (0.13-0.78) | .02 |
| Arachidonic acid | 53/99 | 0.90 (0.65-1.25) | .30 | 9/31 | 0.47 (0.21-1.07) | .07 |
Abbreviations: IM, intestinal metaplasia; LysoPC, lysophosphatidylcholine; OR, odds ratio.
a
Individual metabolites validated to be associated with gastric cancer are shown here, ranked in the same order as given in Table 1. Conditional logistic regression analyses stratified on baseline gastric histopathologic factors were conducted, with adjustment for age, sex, and Helicobacter pylori infection.